Αρχική World News FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma World News FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma Από Ogkologos - 13 Νοεμβρίου, 2024 744 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR HGTV Star Hilary Farr Shares Breast Cancer Battle 16 Δεκεμβρίου, 2021 Man Walks Entire Continent To Spread Awareness About Mental Health &... 16 Ιανουαρίου, 2022 Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... 23 Μαρτίου, 2022 Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... 8 Δεκεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed... Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients... Hopes for the future of cancer research – a video from...